The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One
Now more than ever, pharmaceutical companies’ relationships with physician thought leaders, also known as key opinion leaders (KOLs), are under intense scrutiny. Industry ethicists and watchdogs alike have speculated on the objectivity of medical education presentations and other aspects of KOL involvement during the marketing of new drug therapies. However, the truth is that physician …
The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One Read More »
